Last reviewed · How we verify
NCT06611592: OCD-RT
Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD)
Phase 2 trial testing Pramipexole 0.088mg/tid in Obsessive-Compulsive Disorder in 48 participants. Currently enrolling.
20 August 2028
Quick facts
| Lead sponsor | Clinical Academic Center (2CA-Braga) |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 20 August 2024 |
| Primary completion | 20 August 2028 |
| Estimated completion | 20 August 2028 |
| Sites | 1 location across Portugal |
Drugs / interventions tested
- Pramipexole 0.088mg/tid — full drug profile →
- Pramipexole 0.18 mg/tid — full drug profile →
- Pramipexole 0.35 mg/tid — full drug profile →
Conditions studied
- Obsessive-Compulsive Disorder — all drugs for Obsessive-Compulsive Disorder →
Sponsor
Clinical Academic Center (2CA-Braga)
Who can join
Adults 18 to 64, any sex, with Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The most common and effective treatment for OCD is pharmacological therapy that includes selective serotonin reuptake inhibitors (SSRIs) antidepressants and, in the case of patients resistant to this approach, a combination with antipsychotics. Risperidone and aripiprazole are atypical antipsychotics that act on dopamine (D2) and serotonin receptors. Studies have shown that these drugs are effective in boosting SSRIs for the treatment of OCD in resistant patients. Currently a high percentage of people diagnosed with OCD do not respond to the existing treatments. Pramipexole is a dopaminergic receptor agonist that specifically binds to dopamine D2 and D3 receptors, having demonstrated benefit in resistant depression. The aim of this clinical trial is to explore how pramipexole can act in the treatment of OCD in resistant patients, evaluating its safety and efficacy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06611592
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obsessive-Compulsive Disorder
Currently open trials in the same condition.
- NCT06575075 — Pilot Study of RR-HNK in OCD · Phase 1, PHASE2 · recruiting
- NCT05783817 — MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) · Phase 2 · recruiting
- NCT07065669 — Treating Adolescent Obsessive Compulsive Disorder With Transcranial Magnetic Stimulation · NA · recruiting
- NCT06376734 — Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness · Phase 2 · recruiting
- NCT07000812 — EEG Evaluation of CBT for Obsessive-Compulsive Disorder · NA · active not recruiting
Other Clinical Academic Center (2CA-Braga) trials
Trials by the same sponsor.
- NCT05401032 — Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH. · Phase 2 · recruiting
- NCT05504967 — CT Evaluating the Efficacy of Pre-incisional Local Analgesia With Ropivacaine + Dexamethasone in Pain Management After T · Phase 2 · completed
- NCT05225519 — Effects of Far Infrared Radiation on Fibromyalgia Patients · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06611592 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinical Academic Center (2CA-Braga)
- Last refreshed: 6 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06611592.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing